Correction of murine hemophilia a and immunological differences of factor VIII variants delivered by helper-dependent adenoviral vectors

Molecular Therapy

Volumn 15, Issue 12, 2007, Pages 2080-2087

  Cerullo, Vincenzo ^a   Seiler, Michael P ^a   Mane, Viraj ^a   Cela, Racel ^a   Clarke, Christian ^a   Kaufman, Randal J ^b,c   Pipe, Steven W ^b   Lee, Brendan ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GENE DELETION; HELA CELL; HELPER CELL; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE;

MURINAE; MUS;

EID: 36348953133     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300308     Document Type: Article

References (38)

1. Kaufman, RJ and Pipe, SW (1999). Regulation of factor VIII expression and activity by von Willebrand factor. Thromb Haemost 82: 201-208.
2. Miao, HZ, Sirachainan, N, Palmer, L, Kucab, P, Cunningham, MA, Kaufman, RJ et al. (2004). Bioengineering of coagulation factor VIII for improved secretion. Blood 103: 3412-3419.
3. Pipe, SW and Kaufman, RJ (1997). Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 94: 11851-11856.
4. Vollenweider, F, Kappeler, F, Itin, C and Hauri, HP (1998). Mistargeting of the lectin ERGIC-53 to the endoplasmic reticulum of HeLa cells impairs the secretion of a lysosomal enzyme. J Cell Biol 142 377-389.
5. Campbell, JL and Schekman, R (1997). Selective packaging of cargo molecules into endoplasmic reticulum-derived COPII vesicles. Proc Natl Acad Sci USA 94: 837-842.
6. Kappeler, F, Klopfenstein, DR, Foguet, M, Paccaud, JP and Hauri, HP (1997). The recycling of ERGIC-53 in the early secretary pathway. ERGIC-53 carries a cytosolic endoplasmic reticulum-exit determinant interacting with COPII. J Biol Chem 272: 31801-31808.
7. Pipe, SW (2004). Coagulation factors with improved properties for hemophilia gene therapy. Semin Thromb Hemost 30: 227-237.
8. Chen, HH, Mack, LM, Kelly, R, Ontell, M, Kochanek, S and Clemens, PR (1997). Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 94: 1645-1650.
9. Alemany, R, Dai, Y, Lou, YC, Sethi, E, Prokopenko, E, Josephs, SF et al. (1997). Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations. J Virol Methods 68: 147-159.
10. Parks, RJ and Graham, FL (1997). A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 71: 3293-3298.
11. Toietta, G, Pastore, L, Cerullo, V, Finegold, M, Beaudet, AL and Lee, B (2002). Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther 5: 204-210.
12. Palmer, D and Ng, P (2003). Improved system for helper-dependent adenoviral vector production. Mol Ther 8: 846-852.
13. Mian, A, McCormack, WM Jr., Mane, V, Kleppe, S, Ng, P, Finegold, M et al. (2004). Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus. Mol Ther 10: 492-499.
14. Morsy, MA, Gu, M, Motzel, S, Zhao, J, Lin, J, Su, Q et al. (1998). An adenoviral vector deleted for all viral cooling sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 95: 7866-7871.
15. Toietta, G, Mane, VP, Norona, WS, Finegold, M, Ng, P, McDonagh, AF et al. (2005). Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 102: 3930-3935.
16. Morral, N, O'Neal, W, Rice, K, Leland, M, Kaplan, J, Piedra, PA et al. (1999). Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 96: 12816-12821.
17. McCormack, WM Jr., Seiler, MP, Bertin, TK, Ubhayakar, K, Palmer, DJ, Ng, P et al. (2006). Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. J Thromb Haemost 4: 1218-1225.
18. Morral, N, O'Neal, WK, Rice, K, Leland, MM, Piedra, PA, Aguilar-Cordova, E et al. (2002). Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 13: 143-154.
19. Nunes, FA, Furth, EE, Wilson, JM and Raper, SE (1999). Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration. Hum Gene Ther 10: 2515-2526.
20. Brunetti-Pierri, N, Palmer, DJ, Beaudet, AL, Carey, KD, Finegold, M and Ng, P (2004). Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15: 35-46.
21. Jooss, K, Ertl, HC and Wilson, JM (1999). Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol 72: 2945-2954.
22. Mane, VP, Toietta, G, McCormack, WM, Conde, I, Clarke, C, Palmer, D et al. (2006). Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors. Gene Ther 13: 1272-1280.
23. Morral, N, Parks, RJ, Zhou, H, Langston, C, Schiedner, G, Quinones J, et al. (1998). High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 9: 2709-2716.
24. Beale, EG, Clouthier, DE and Hammer, RE (1992). Cell-specific expression of cytosolic phosphoenolpyruvate carboxykinase in transgenic mice. FASEB J 6: 3330-3337.
25. Pittman, DD, Alderman, EM, Tomkinson, KN, Wang, JH, Giles, AR and Kaufman, RJ, (1993). Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 81: 2925-2935.
26. Toole, JJ, Pittman, DD, Orr, EC, Murtha, P, Wasley, LC and Kaufman, RJ (1986). A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 83: 5939-5942.
27. Swaroop, M, Moussalli, M, Pipe, SW and Kaufman, RJ (1997). Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem 272: 24121-24124.
28. Marquette, KA, Pittman, DD and Kaufman, RJ (1995). A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem 270: 10297-10303.
29. Bi, L, Lawler, AM, Antonarakis, SE, High, KA, Gearhart, JD and Kazazian, HH Jr. (1995). Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 10: 119-121.
30. Kaufman, RJ, Pipe, SW, Tagliavacca, L, Swaroop, M and Moussalli, M (1997). Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 8: S3-S14.
31. Tagliavacca, L, Wang, Q and Kaufman, RJ (2000). ATP-dependent dissociation of non-disulfide-linked aggregates of coagulation factor VIII is a rate-limiting step for secretion. Biochemistry 39: 1973-1981.
32. Reddy, PS, Sakhuja, K, Ganesh, S, Yang, L, Kayda, D, Brann, T et al. (2002). Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 5: 63-73.
33. Chuah, MK, Schiedner, G, Thorrez, L, Brown, B, Johnston, M, Gillijns, V et al. (2003). Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 101: 1734-1743.
34. Ehrhardt, A, Xu, H, Dillow, AM, Bellinger, DA, Nichols, TC and Kay, MA (2003). A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 102: 2403-2411.
35. Brown, BD, Shi, CX, Powell, S, Hurlbut, D, Graham, FL and Lillicrap, D (2004). Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 103: 804-810.
36. Qian, J, Borovok, M, Bi, L, Kazazian, HH Jr. and Hoyer, LW (1999). Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 81: 240-244.
37. Kasper, CK, Aledort, L, Aronson, D, Counts, R, Edson, JR, van Eys, J, et al. (1975). Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34: 612.
38. Cerullo, V, Seiler, MP, Mane, V, Brunetti-Pierri, N, Clarke, C, Bertin, TK et al. (2007). Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 15 378-385.